Wells Fargo’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-150
| Closed | -$109 | – | 7548 |
|
|
2026
Q1 | $109 | Hold |
150
| – | – | ﹤0.01% | 6493 |
|
|
2025
Q4 | $837 | Sell |
150
-200
| -57% | -$2.22K | ﹤0.01% | 6297 |
|
|
2025
Q3 | $2.58K | Buy |
350
+200
| +133% | +$1.7K | ﹤0.01% | 6153 |
|
|
2025
Q2 | $1.14K | Hold |
150
| – | – | ﹤0.01% | 6296 |
|
|
2025
Q1 | $2.86K | Buy |
+150
| New | +$4.71K | ﹤0.01% | 6111 |
|
|
2024
Q2 | – | Sell |
-9
| Closed | -$662 | – | 7378 |
|
|
2024
Q1 | $662 | Buy |
9
+2
| +29% | +$158 | ﹤0.01% | 6236 |
|
|
2023
Q4 | $716 | Sell |
7
-250
| -97% | -$22.4K | ﹤0.01% | 6310 |
|
|
2023
Q3 | $25K | Buy |
257
+1
| +0.4% | +$93 | ﹤0.01% | 5507 |
|
|
2023
Q2 | $30K | Buy |
256
+250
| +4,167% | +$31.7K | ﹤0.01% | 5617 |
|
|
2023
Q1 | $461 | Buy |
6
+1
| +20% | +$87 | ﹤0.01% | 6572 |
|
|
2022
Q4 | $463 | Buy |
5
+1
| +25% | +$76 | ﹤0.01% | 6408 |
|
|
2022
Q3 | $0 | Hold |
4
| – | – | ﹤0.01% | 7250 |
|
|
2022
Q2 | $0 | Sell |
4
-1
| -20% | -$35 | ﹤0.01% | 7380 |
|
|
2022
Q1 | $0 | Hold |
5
| – | – | ﹤0.01% | 7697 |
|
|
2021
Q4 | $0 | Buy |
5
+3
| +150% | +$214 | ﹤0.01% | 7712 |
|
|
2021
Q3 | $0 | Hold |
2
| – | – | ﹤0.01% | 7424 |
|
|
2021
Q2 | $0 | Hold |
2
| – | – | ﹤0.01% | 7350 |
|
|
2021
Q1 | $0 | Buy |
+2
| New | +$334 | ﹤0.01% | 7299 |
|
Other funds holding RVPH
Wells Fargo's RVPH Position: Q2 2026 in Review
Wells Fargo sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q2 2026, closing a stake of 150 shares — an estimated $109 sold.
Wells Fargo first reported a position in RVPH in Q1 2021 and held it in 18 quarters. The position peaked at $30K in Q2 2023. 5 funds tracked by Wall St. Rank hold RVPH as of Q2 2026.
- Wells Fargo reported no remaining REVIVA PHARMA HLDGS INC position as of Q2 2026 after selling out during the quarter.
- Wells Fargo sold 150 REVIVA PHARMA HLDGS INC shares in Q2 2026, an estimated $109.
- Wells Fargo first reported a position in REVIVA PHARMA HLDGS INC in Q1 2021 and held it in 18 quarters.
- Wells Fargo's REVIVA PHARMA HLDGS INC position peaked at $30K in Q2 2023.
- 5 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.